Short answer
Mostly no. Meta prohibits the promotion of unsafe or unapproved supplements and prescription drugs by unauthorised advertisers, and most peptides sold through telehealth fall on the wrong side of that line. MedScale, a growth agency working exclusively with telehealth brands, treats peptides as a category where paid social is generally closed rather than merely difficult, and plans the channel mix accordingly instead of burning an ad account discovering it.
The honest answer
Most peptide brands asking this question want to hear that the right creative approach unlocks the channel. MedScale works exclusively with telehealth brands, and giving that answer would be dishonest: for the majority of peptides sold through telehealth, Meta is closed rather than difficult, and the constraint is the product rather than the advertising.
This is a different situation from GLP-1, where the category is permitted and the discipline is in how creative is structured. In peptides, the underlying regulatory status of the substance is usually what blocks the channel, and no amount of copywriting changes it.
Why the policy catches this category
Meta prohibits the promotion of unsafe substances, unapproved supplements, and prescription drugs promoted by advertisers who are not authorised to do so. Peptides commonly sold in telehealth intersect all three, because many are not approved for human therapeutic use, several are sold under research framing, and those dispensed through prescribers are prescription products.
The route into a violation therefore does not depend on how aggressive the creative is. A restrained, factual ad for a product the platform treats as unapproved is still an ad for a product the platform treats as unapproved.
The research chemical framing makes it worse, not better
A common workaround is to describe peptides as research chemicals not for human consumption. As an advertising strategy this is close to self-defeating: it states explicitly that the product is not approved for the use the audience is buying it for, and it creates a mismatch between the ad and the actual funnel.
Platforms assess what the funnel does rather than what the disclaimer says. A research framing paired with a consumer purchase flow reads as misrepresentation, which is a second policy problem stacked on the first.
What partially works
Some brands do run paid social successfully, and the pattern is consistent: they advertise something other than the peptide.
- Advertising the clinical consultation or the broader programme, where peptides are one possible outcome rather than the offer.
- Advertising an adjacent approved category, with peptides discovered later in the relationship.
- Brand and category education that does not promote a specific restricted substance.
Each of these is a genuine narrowing of the message, and each requires the destination page to match. An ad about a consultation that lands on a peptide product page will be assessed on the page.
The cost of finding out the hard way
The expensive version of this lesson is testing peptide creative until the account is restricted, then discovering that the restriction affects linked assets in the same Business Manager, including the ones supporting product lines that were compliant.
MedScale advises structuring business assets so that a restricted category cannot take down a compliant one, and treating peptides as a channel-mix problem to be solved outside paid social rather than a creative problem to be solved inside it.
Common questions
- 01Can I advertise peptides if a licensed clinician prescribes them?
- A prescriber relationship addresses the clinical question but not the platform policy question, since restrictions on promoting prescription and unapproved products apply to the advertiser regardless. Prescription involvement can also bring certification requirements into scope on top of the existing restrictions.
- 02What happens if I run peptide ads anyway?
- The realistic outcomes range from disapprovals to account restriction, and enforcement can extend to linked assets in the same Business Manager. The risk that matters most is not the rejected ad but the exposure of compliant product lines sharing the same business structure.
- 03Is it different if I only mention peptides on the landing page?
- No, because Meta reviews the destination as part of the ad. Moving the restricted content from the creative to the page keeps it inside the scope of review, and page-level violations are a common cause of disapproval in this category.
- 04Are any peptides straightforwardly advertisable?
- Status varies by substance and by jurisdiction, and a small number sit in a materially different position from the research-framed majority. Each substance needs to be assessed individually with regulatory advice rather than treated as part of a single category.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.